TFF PHARMACEUTICALS, INC. (TFFP): Price and Financial Metrics
TFFP Price/Volume Stats
| Current price | $3.01 | 52-week high | $21.25 |
| Prev. close | $2.97 | 52-week low | $2.51 |
| Day low | $2.79 | Volume | 12,712 |
| Day high | $3.13 | Avg. volume | 28,365 |
| 50-day MA | $6.02 | Dividend yield | N/A |
| 200-day MA | $7.50 | Market Cap | 7.58M |
TFFP Stock Price Chart Interactive Chart >
TFF PHARMACEUTICALS, INC. (TFFP) Company Bio
TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. The Company develops powder and molecule drugs for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals serves clients in the State of Texas.
Latest TFFP News From Around the Web
Below are the latest news stories about TFF PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TFFP as an investment opportunity.
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACTreatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute r |
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TACCompany to host conference call and webcast on Tuesday, December 19th at 8:30 am ETFORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and |
TFF Pharmaceuticals Announces Reverse Stock SplitCommon Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. T |
TFF Pharmaceuticals Appoints Thomas B. King to Board of DirectorsFORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceu |
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of DirectorsFORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. “I am pleased to welcome Dr. Patane to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Ph |
TFFP Price Returns
| 1-mo | -59.32% |
| 3-mo | -40.63% |
| 6-mo | -61.70% |
| 1-year | -78.11% |
| 3-year | -98.98% |
| 5-year | N/A |
| YTD | -57.12% |
| 2023 | -73.26% |
| 2022 | -88.16% |
| 2021 | -38.06% |
| 2020 | 167.66% |
| 2019 | N/A |
Loading social stream, please wait...